Solutions for TME and Tumor Lymphangiogenesis
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides comprehensive solutions for the study of tumor lymphangiogenesis to help researchers successfully achieve their research goals.
The tumor microenvironment is the internal environment in which tumors occur and develop, including tumor cells themselves, microvessels, microlymphatic vessels, interstitial cells, tissue fluid, immune and inflammatory cells, many cytokines, and a small amount of infiltrating cells. Tumor cells proliferate indefinitely, constantly creating an external tissue environment suitable for their own growth, and gradually forming a microenvironment that is different from that formed by normal cells and their surrounding tissues. The microenvironment has biological properties such as tissue hypoxia, acidosis, interstitial hypertension, production of a large number of growth factors / proteolytic enzymes and immune inflammatory responses, which play an important role in tumor lymphangiogenesis and tumor metastasis.
Tumor lymphangiogenesis refers to the formation of new lymphatic capillaries around the tumor in situ tissue or in the tumor tissue, which is the process of budding and further differentiation of the host vascular embryo main vein or existing lymphatic vessels to form new lymphatic capillaries process.
The tumor microenvironment is a complex and comprehensive system, and it is an essential functional unit to protect and support the occurrence, development, metastasis and recurrence of tumors. It has the characteristics of diverse feedback control mechanisms and unique metabolic pathways. With the continuous discovery of lymphatic vessel markers and the further clarification of the mechanism of lymph node metastasis, the importance of tumor microenvironment for recurrence and metastasis has become increasingly apparent. By regulating the pH and IFP of the microenvironment, improving the hypoxia state, and inhibiting the promotion of growth factors and inflammatory mediators on metastasis, the occurrence of tumor lymph node metastasis can be effectively controlled. Targeting the microenvironment to inhibit tumor growth and metastasis is the direction of future tumor research. Alfa Oncology develops multiple technologies, hoping to provide convenient conditions for studying the influence of tumor microenvironment on tumor lymphangiogenesis, thereby providing drug delivery guidance and treatment methods for clinical tumors.
3D culture model. As far as angiogenesis is concerned, two-dimensional cell culture cannot form a three-dimensional vascular system, so it is not suitable for the study of angiogenesis, collateral association and remodeling. To this end, we have established a 3D tumor organoid model, which can co-culture a variety of different cell types and simulate microenvironmental conditions (such as immune microenvironment, tumor angiogenesis, etc.), which facilitates our study of tumor lymphangiogenesis and its regulation, lymphatic endothelial markers, and lymphangiogenesis and tumor metastasis.
Single-cell sequencing technology. Sequencing whole tumors often masks heterogeneity between cells. Emerging single-cell sequencing technologies analyze the genome, transcriptome or epigenetics at the single-cell level, which can reveal the evolution or degree of variation and interconnection between different cells, deepen the understanding of single cells, and facilitate the discovery of tumor lymphatic vessels Markers and understanding of tumor lymphangiogenesis and lymph node metastasis.
Various imaging techniques are available to assess tumor lymphangiogenesis. Each method has its own unique advantages and scope of application, but all can non-invasively and rapidly evaluate tumor angiogenesis and anti-angiogenic effects in vivo. Through these techniques, more and better tumor lymphatic vessel marker molecules have been discovered, suitable targets for blocking and destroying tumor lymphangiogenesis have been found, and effective anti-tumor lymphangiogenesis drugs have been developed. It is used for early diagnosis, recurrence monitoring, clinical medication guidance and efficacy evaluation of tumors.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.